New Orleans hosted this year’s AAPS PharmSci 360 at the Ernest N. Morial Convention Center. For those fortunate enough to ...
AstraZeneca's rare disease unit Alexion has won regulatory approval in the US and EU for Klygefa as a generalised myasthenia ...
Eli Lilly has added yet another name to its list of M&A deals this year after agreeing to buy blood disorder specialist Calytrix Bio for up to $1.5 billion. If it goes through, the deal will give ...
The FDA has said it cannot approve Summit Therapeutics and Akeso's PD-1xVEGF inhibitor ivonescimab, delaying a drug that is ...
China has overtaken Europe as the preferred location for healthcare investing, according to a new report from Jefferies, ...
John Tsai is currently CEO of UK biotech Forcefield Therapeutics and a partner at investment group Syncona. Daiichi Sankyo has named John Tsai as its new global head of R&D, replacing Ken Takeshita, ...
The takeover deal – worth up to $1.15 billion including $550 million in upfront cash – will upgrade the Dutch biotech's ...
Just a few months after being formed, China's Funnel Biosciences has signed a $2 billion-plus partnership with Third Rock ...
Hims & Hers is also offering compounded formulations of other unapproved peptides, including sermorelin, which some people ...
Bayer's oral Factor XIa inhibitor asundexian has been approved in its first market, China, for secondary stroke prevention, beating its main rival therapy from Bristol Myers Squibb and Johnson & ...
Patients with muscle-invasive bladder cancer can now receive NHS treatment with a regimen of MSD's Keytruda and Astellas' ...
UK-based startup Oyster Therapeutics has raised $60 million in first-round financing that will be used to advance its tau ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results